Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07028125 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

Study acronym: CANIQOL
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 16 → 19 locationsv5
  2. Study sites: 10 to 16v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2025 to Oct 1, 2025
    • Site details revised at 10 of 10 sites
    v3
  4. Start date: Jul 2025 to Sep 2025v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of the study is to evaluate the impact of digital monitoring of self-reported symptoms (PROs) on the adjustment of treatment management in patients treated with cabozantinib plus nivolumab for advanced clear cell renal cell carcinoma (RCC) in real life during the first 3 months of combined treatment
Trial Details
NCT Number NCT07028125
Lead Sponsor Centre Francois Baclesse
Conditions
(from sponsor)		 Renal Cell Carcinoma (Kidney Cancer), Metastatic Renal Cell Carcinoma, Locally Advanced
Related terms Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis
Enrollment 83 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov